Ro 0437626 

Ro 0437626 is a selective purinergic (P2X₁) receptor antagonist (IC₅₀ = 3 μM), but shows low affinity for P2X2, P2X3 and P2X2/3 receptors (IC₅₀ > 100 μM)^[1].

IC50: 3 μM (P2X1 receptor)

Ro 0437626 reduces PMA-evoked Ca²⁺entry with 6.8 ± 4.7% of control^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ro 0437626 (1 and 10 μmol/kg; i.v.) causes a reduction in postinfusion isovolumetric contractions^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

525.66

C₂₇H₃₅N₅O₄S

134362-79-1

O=C(C1=NC2=CC=CC=C2N1)N[C@H](CC3=CSC=N3)C(N[C@@H](CC4CCCCC4)[C@@H](O)[C@H](C5CC5)O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jaime-Figueroa S, et al. Discovery and synthesis of a novel and selective drug-like P2X(1) antagonist. Bioorg Med Chem Lett. 2005;15(13):3292-3295.  [Content Brief]

  [2]. Harper MT, et al. Phorbol ester-evoked Ca2+ signaling in human platelets is via autocrine activation of P(2X1) receptors, not a novel non-capacitative Ca2+ entry. J Thromb Haemost. 2010;8(7):1604-1613.  [Content Brief]

  [3]. King BF, et al. Investigation of the effects of P2 purinoceptor ligands on the micturition reflex in female urethane-anaesthetized rats. Br J Pharmacol. 2004;142(3):519-530.  [Content Brief]